PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Pfizer, MedImmune, Roche, and Bristol-Myers Squibb intended to find methods to enable prediction and prevention of PML associated with immunomodulatory and immunosuppressive treatments.
Public Webinar: The Role of Consortia in Addressing Rare Adverse Events We will host a public webinar with representatives from MHRA, Health Canada, and the Consortium on Wednesday, July 27th at 12 PM Eastern. Register
Review Article Published “Progressive Multifocal Leukoencephalopathy: Current Treatment Options and Future Perspectives,” authored by members of the PML Consortium Clinical and Research Working Groups, has been published in Therapeutic Advances in Neurological Disorders. Access the full article via PubMed.